Relevant bibliographies by topics / Pharmacology / Journal articles
To see the other types of publications on this topic, follow the link: Pharmacology.

Journal articles on the topic 'Pharmacology'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 March 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmacology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mortin, Lawrence I., Christopher J. Horvath, and Michael S. Wyand. "Safety Pharmacology Screening: Practical Problems in Drug Development." International Journal of Toxicology 16, no. 1 (January 1997): 41–65. http://dx.doi.org/10.1080/109158197227350.

Full text
Abstract:
Undesired pharmacologic activities of novel drugs or biologies may limit development of a therapeutic prior to the characterization of any toxicologic effects. In rodent species, general pharmacology assays have traditionally been used to screen new agents for pharmacologic effects on the central and peripheral nervous systems, the autonomic nervous system and smooth muscles, the respiratory and cardiovascular systems, the digestive system, and the physiologic mechanisms of water and electrolyte balance. In large animal species, such as dogs and nonhuman primates, smaller numbers of animals per study limit their use for screening assays, but these species may play an important role in more detailed mechanistic studies. For drugs and biologies that must be tested in nonhuman primates because of species-specific action of the test agent, functional pharmacologic data are often collected during acute or subacute toxicity studies. This requires careful experimental design to minimize any impact pharmacologic effects or instrumentation may have on the assessment of toxicity. In addition, with many new therapies targeted at immunologic diseases, the pharmacologic effect of therapeutics on the immune system presents new challenges for pharmacologic profiling. The application of pharmacology assays by organ system in both rodent and large animal species are discussed, as well as practical issues in assessing pharmacology endpoints in the context of toxicity studies.
APA, Harvard, Vancouver, ISO, and other styles
2

Hite, Mark. "Safety Pharmacology Approaches." International Journal of Toxicology 16, no. 1 (January 1997): 23–31. http://dx.doi.org/10.1080/109158197227332.

Full text
Abstract:
This article presents views of a discipline termed safety pharmacology or general pharmacology. This is an area that provides information through empirical studies on new pharmacologic agents at doses above those thought to be efficacious and the no-toxicologic-effect level (NOEL) above which unwanted effects might occur. The usefulness of batteries of tests is discussed, and comments are made about the value of these in the drug developmental process.
APA, Harvard, Vancouver, ISO, and other styles
3

Teixeira, Marcus Zulian. ""˜Paradoxical pharmacology": therapeutic strategy used by the "˜homeopathic pharmacology" for more than two centuries." International Journal of High Dilution Research - ISSN 1982-6206 13, no. 49 (October 24, 2021): 207–26. http://dx.doi.org/10.51910/ijhdr.v13i49.714.

Full text
Abstract:
Using the empirical or phenomenological research method by observing the effects of drugs in the human physiology, Samuel Hahnemann proposed the homeopathic treatment. He synthesized modern pharmacodynamic in the ‘primary action’ of the drugs and in the consequent and opposite ‘secondary action’ or ‘vital reaction’ of the organism. Noting that drugs with ‘contrary’ primary action to the symptoms of the diseases caused worsening of the symptoms after its withdrawal, as a result of secondary action of the organism, Hahnemann proposed using this vital reaction in a curative way, administering to sick individuals the drugs that caused ‘similar’ symptoms in healthy individuals (therapeutic use of the similitude principle). According to the clinical and experimental pharmacology, this secondary action (vital reaction) of the organism is observed in the ‘rebound effect’ or ‘paradoxical reaction’ of several classes of drugs, which is the scientific basis of the ‘homeopathic pharmacology’. In the last decade, exponents of modern pharmacology have suggested the therapeutic use of the paradoxical reaction (‘paradoxical pharmacology’), proposing the use of drugs that cause an exacerbation of the disease in the short term to treat these same diseases in the long-term. In this review, we compare the various aspects between the ‘homeopathic pharmacology’ and the ‘paradoxical pharmacology’, reinforcing the validity of homeopathic assumptions and expanding the knowledge to optimize both proposals.
APA, Harvard, Vancouver, ISO, and other styles
4

Nureye, Dejen. "Reverse Pharmacology and Network Pharmacology: Principles and Applications in Herbal Medicine." Journal of Traditional Medicine & Applications 3, no. 2 (November 21, 2024): 01–24. http://dx.doi.org/10.33140/jtma.03.02.06.

Full text
Abstract:
Drugs that were therapeutic were frequently unintentionally found in medicinal plants during the early days of pharmacology. Cost, time, and toxicity are the three main bottlenecks that can be reduced by the recently developed academic field of reverse pharmacology. Reversing the typical “laboratory-to-clinic” drug discovery pipeline approach to “clinic-to-laboratories” is the idea behind reverse pharmacology, which was influenced by traditional knowledge. Reverse pharmacology aims to optimise the safety, efficacy, and acceptability of natural product leads by studying their mechanisms of action at various levels of biological organisation and by applying pertinent sciences to these findings. New Chemical Entities must go through the drawn-out pre-clinical and clinical research phases of the traditional drug discovery and development process. Conversely, the reverse pharmacology path represents a cyclical approach to drug discovery and development. Drug development from natural products, such as anti-malarial, antihypertensive, and anti-Parkinson’s medicines, can benefit from the application of reverse pharmacology. The one drug, one target, and one illness method used in drug discovery today is becoming less and less effective. Drug research is quickly embracing the idea of developing multi-target therapeutics to treat complex illnesses. In this context, disease mechanisms are defined by network pharmacology as networks that are best targeted by a combination of treatments that function in concert. Recently, network pharmacology has gained popularity as a means of better understanding the mode of action of herbal remedies. Network pharmacology has several benefits, such as controlling the signalling route through several channels, improving therapeutic efficacy, lowering adverse effects, raising clinical trial success rates, and lowering drug discovery expenses. The field of network pharmacology has its roots in traditional Chinese medicine and has developed alongside it. Static networks and dynamic networks are the two broad groups into which network pharmacology-based techniques fall. The main goals of network pharmacology research are to find genes linked to compounds and diseases, build a network, and then analyse and visualise the network. In order to properly validate the interaction between highly active constituents and their potential targets, further network validation is carried out in the end. Several applications for network pharmacology can be found in drug research, pharmacology, and traditional medicine.
APA, Harvard, Vancouver, ISO, and other styles
5

Sepúlveda, Pablo O., Valeria Epulef, and Gustavo Campos. "Why do We Use the Concepts of Adult Anesthesia Pharmacology in Developing Brains? Will It Have an Impact on Outcomes? Challenges in Neuromonitoring and Pharmacology in Pediatric Anesthesia." Journal of Clinical Medicine 10, no. 10 (May 18, 2021): 2175. http://dx.doi.org/10.3390/jcm10102175.

Full text
Abstract:
Background: Pediatric sedation and anesthesia techniques have plenty of difficulties and challenges. Data on the pharmacologic, electroencephalographic, and neurologic response to anesthesia at different brain development times are only partially known. New data in neuroscience, pharmacology, and intraoperative neuromonitoring will impact changing concepts and clinical practice. In this article, we develop a conversation to guide the debate and search for a view more attuned to the updated knowledge in neurodevelopment, electroencephalography, and clinical pharmacology for the anesthesiologic practice in the pediatric population.
APA, Harvard, Vancouver, ISO, and other styles
6

Mahmoud, Jahangir. "Clinical pharmacology of anxiolytics." Psychology and Mental Health Care 2, no. 1 (March 27, 2018): 01–04. http://dx.doi.org/10.31579/2637-8892/022.

Full text
Abstract:
It is increasingly difficult to define what an anxiolytic is, since anxiety is multiple although many symptoms are common. On the other hand the most used drugs in different forms of anxiety were first used as antidepressants. This article tries to put together the different effective anxiolytics used and describe their pharmacology.
APA, Harvard, Vancouver, ISO, and other styles
7

Adi Try Wurjatmiko. "The Effects of Music Therapy Intervention on the Pain and Anxiety Levels of Cancer Patient: A Systematic Review." International Journal of Nursing Education 11, no. 4 (November 21, 2019): 14–18. http://dx.doi.org/10.37506/ijone.v11i4.3936.

Full text
Abstract:
Cancer constitutes one of illnesses which frequently causes pain and anxiety. The management of cancer pain comprises the pharmacology and non-pharmacology. The pharmacologic management, at some points, fails to provide a complete relief from the pain and instead gives rises to unwanted side-effects on the patients that necessitate the employment of non-pharmacologic management such as music therapy. The purpose of this systematic review is to discover the effects of music therapy on the pain and anxiety levels on the cancer patient. Systematic Review encompasses literature obtained from library research and internet research using search engine such as PubMed, Medline, Proquest, dan Elsevier. The articles comprise the full text journals published between the years of 2009-2016. 87.50% out of 8 articles (1 systematic review) demonstrates that music therapy effectively alleviates the pain to 75.00% and lowers the anxiety level, and 12.50% of insignificant palliative effect in terms of the pain and anxiety. Music therapy is an effective non-pharmacologic therapy to alleviate or relieve the cancer patients of the resultant pain and anxiety.
APA, Harvard, Vancouver, ISO, and other styles
8

Wall, Nathan R., Ryan N. Fuller, Ann Morcos, and Marino De Leon. "Pancreatic Cancer Health Disparity: Pharmacologic Anthropology." Cancers 15, no. 20 (October 20, 2023): 5070. http://dx.doi.org/10.3390/cancers15205070.

Full text
Abstract:
Pancreatic cancer (PCa) remains a formidable global health challenge, with high mortality rates and limited treatment options. While advancements in pharmacology have led to improved outcomes for various cancers, PCa continues to exhibit significant health disparities, disproportionately affecting certain populations. This paper explores the intersection of pharmacology and anthropology in understanding the health disparities associated with PCa. By considering the socio-cultural, economic, and behavioral factors that influence the development, diagnosis, treatment, and outcomes of PCa, pharmacologic anthropology provides a comprehensive framework to address these disparities and improve patient care.
APA, Harvard, Vancouver, ISO, and other styles
9

Anand Dhonde, Shreya, and Rahul Sudam Jadhav. "New Developments in Behavioural Pharmacology." International Journal of Science and Research (IJSR) 12, no. 10 (October 5, 2023): 117–21. http://dx.doi.org/10.21275/mr23928202832.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Karlsen Bjånes, Tormod, Espen Mjåset Hjertø, Lars Lønne, Lena Aronsen, Jon Andsnes Berg, Stein Bergan, Grim Otto Berg-Hansen, et al. "Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services." Clinical Therapeutics 38, no. 1 (January 2016): 222–26. http://dx.doi.org/10.1016/j.clinthera.2015.10.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Pupo, Andre S., and Kenneth P. Minneman. "Adrenergic Pharmacology: Focus on the Central Nervous System." CNS Spectrums 6, no. 8 (August 2001): 656–62. http://dx.doi.org/10.1017/s1092852900001346.

Full text
Abstract:
ABSTRACTNorepinephrine and epinephrine are involved in the control of several important functions of the central nervous system (CNS), including sleep, arousal, mood, appetite, and autonomic outflow. Catecholamines control these functions through activation of a family of adrenergic receptors (ARs). The ARs are divided into three subfamilies (α1, α2, and β) based on their pharmacologic properties, signaling mechanisms, and structure. ARs in the CNS are targets for several therapeutic agents used in the treatment of depression, obesity, hypertension, and other diseases. Not much is known, however, about the role of specific AR sub-types in the actions of these drugs. In this paper, we provide an overview of adrenergic pharmacology in the CNS, focusing on the pharmacologic properties of subtype-selective AR agonists and antagonists, the accessibility of these drugs to the CNS, and the distribution of ARs in different areas of the brain.
APA, Harvard, Vancouver, ISO, and other styles
12

Paiman, Arif, Ahmad Mohammadi, Rafia Inam, Aqsa Ameen, and Mubashar Rehman. "Oral Drug Delivery to the Experimental Animals, A Mini Review." Global Drug Design & Development Review I, no. I (December 30, 2016): 19–26. http://dx.doi.org/10.31703/gdddr.2016(i-i).03.

Full text
Abstract:
In several pharmacologic, pharmacology, and alternative medicine studies, oral administration of medication or test substances to experimental animals is needed. It is clinically sound and recommended to administer test substances to experimental animals along the same route that they are taken or expected to be taken by humans as general bioavailability; the pharmacology and pharmacology parameters obtained for the drug will depend significantly on the route chosen to administer it. The lack of ready access to high-quality oral tubing built for different species, as well as a widespread lack of technical expertise to properly use out-of-the-box techniques in this part of the world, has made this route controversial among medicine scientists. The typical problems and difficulties associated with the oral administration of test product solutions were avoided by mistreating either the syringe alone or incorporating it into the animals feeds or drinkables. This jury-rigged oral tubing was also used to ensure that the expected doses were correctly administered in each case.
APA, Harvard, Vancouver, ISO, and other styles
13

Muldoon, Leslie L., Carole Soussain, Kristoph Jahnke, Conrad Johanson, Tali Siegal, Quentin R. Smith, Walter A. Hall, et al. "Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check." Journal of Clinical Oncology 25, no. 16 (June 1, 2007): 2295–305. http://dx.doi.org/10.1200/jco.2006.09.9861.

Full text
Abstract:
PurposeThis review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006.ResultsChemotherapeutic regimens in brain tumor therapy have often emerged from empirical clinical studies with retrospective pharmacologic explanations, rather than prospective trials of rational chemotherapeutic approaches. Brain tumors are largely composed of CNS metastases of systemic cancers. Primary brain tumors, such as glioblastoma multiforme or primary CNS lymphomas, are less common. Few of these tumors have well-defined optimal treatment. Brain tumors are protected from systemic chemotherapy by the blood-brain barrier (BBB) and by intrinsic properties of the tumors. Pharmacologic studies of delivery of conventional chemotherapeutics and novel therapeutics showing actual tumor concentrations and biologic effect are lacking.ConclusionIn this article, we review drug delivery across the BBB, as well as blood-tumor and –cerebrospinal fluid (CSF) barriers, and mechanisms to increase drug delivery to CNS and CSF tumors. Because of the difficulty in treating CNS tumors, innovative treatments and alternative delivery techniques involving brain/cord capillaries, choroid plexus, and CSF are needed.
APA, Harvard, Vancouver, ISO, and other styles
14

Aronson, Jeffrey K. "Integrating pharmacology and clinical pharmacology." British Journal of Clinical Pharmacology 71, no. 5 (April 11, 2011): 787–90. http://dx.doi.org/10.1111/j.1365-2125.2011.03910.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Somberg, John C. "Clinical Pharmacology: Medicine or Pharmacology." Journal of Clinical Pharmacology 32, no. 9 (September 1992): 773. http://dx.doi.org/10.1002/j.1552-4604.1992.tb03882.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Makhmaraimov, Sh T. "Role Play Technology In Pharmacology Classes." American Journal of Medical Sciences and Pharmaceutical Research 02, no. 11 (November 17, 2020): 1–7. http://dx.doi.org/10.37547/tajmspr/volume02issue11-01.

Full text
Abstract:
The article describes the methodology of using the technology of role-playing games in practical classes at the university, which belongs to the advanced pedagogical methods. For, a problem situation, solving a problem, finding a suitable solution to a problem together teaches students to think wider, deeply analyze the situation, move away from analyzing the situation, paves the way for mental and emotional development.
APA, Harvard, Vancouver, ISO, and other styles
17

Bereda, Gudisa. "Clinical Pharmacology of Vancomycin in Pediatrics." Pharmacy and Drug Development 1, no. 2 (December 8, 2022): 01–04. http://dx.doi.org/10.58489/2836-2322/009.

Full text
Abstract:
Vancomycin plays an indispensable therapeutic function in managing severe infections caused by MRSA in the children population. Preponderance children dosing references for vancomycin recommend a daily dose of 40 mg/kg/day for empirical treatment, while a dose of 60 mg/kg/day is recommended for CNS infections. Vancomycin is absorbed in fewer amounts through PO in GIT, it is thus IV administered. IV infusions of vancomycin perhaps cause pain, phlebitis, erythema, urticaria, flushing, hypotension, tachycardia and the red man syndrome. Coincident administration of vancomycin with amphotericin-B, NSAIDs, aminoglycosides, cisplatin and other nephrotoxic agents perhaps exaggerated the risk of nephrotoxicity. Concomitant administration of vancomycin and furosemide, aminoglycosides, ethacrynic acid, etc perhaps increase the risk of ototoxicity. Coadministration of vancomycin and vecuronium increases the risk of neuromuscular blockage. If vancomycin and zidovudine are administered together, they increase the risk of neutropenia.
APA, Harvard, Vancouver, ISO, and other styles
18

Lingadahalli Puttachar, Srikrishna, Teja Moreshwar Godkar, Vinisha Mascarenhas, Desiree Delicia Fernandes, Aliya Mohammad Sayed, Shawna Correia, Sahil Naik, et al. "Phytochemistry and Pharmacology of Coleus Forskohlii." International Journal of Science and Research (IJSR) 13, no. 5 (May 5, 2024): 1234–42. http://dx.doi.org/10.21275/sr24512141340.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Xu, Sijin, Shuaipeng Chen, Wenxin Xia, Hong Sui, and Xueyan Fu. "Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity." Molecules 27, no. 9 (May 7, 2022): 3009. http://dx.doi.org/10.3390/molecules27093009.

Full text
Abstract:
Hyperoside is an active ingredient in plants, such as Hypericum monogynum in Hypericaceae, Crataegus pinnatifida in Rosaceae and Polygonum aviculare in Polygonaceae. Its pharmacologic effects include preventing cancer and protecting the brain, neurons, heart, kidneys, lung, blood vessels, bones, joints and liver, among others. Pharmacokinetic analysis of hyperoside has revealed that it mainly accumulates in the kidney. However, long-term application of high-dose hyperoside should be avoided in clinical practice because of its renal toxicity. This review summarises the structure, synthesis, pharmacology, pharmacokinetics and toxicity of hyperoside.
APA, Harvard, Vancouver, ISO, and other styles
20

Narayanan-Sankar, M., and R. I. Clyman. "Pharmacology Review: Pharmacologic Closure of Patent Ductus Arteriosus in the Neonate." NeoReviews 4, no. 8 (August 1, 2003): 215e—221. http://dx.doi.org/10.1542/neo.4-8-e215.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Baraona, L. Kim, Dawn Lovelace, Julie L. Daniels, and Linda McDaniel. "Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women." Journal of Midwifery & Women's Health 62, no. 3 (May 2017): 253–69. http://dx.doi.org/10.1111/jmwh.12616.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 14, no. 1 (January 1987): 40. http://dx.doi.org/10.1097/00152192-198701000-00035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

&NA;, &NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 14, no. 2 (March 1987): 88. http://dx.doi.org/10.1097/00152192-198703000-00058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Boarini, Joy. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 14, no. 3 (May 1987): 130. http://dx.doi.org/10.1097/00152192-198705000-00048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 14, no. 4 (July 1987): 176. http://dx.doi.org/10.1097/00152192-198707000-00038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 14, no. 5 (September 1987): 223. http://dx.doi.org/10.1097/00152192-198709000-00025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

&NA;, &NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 15, no. 1 (January 1988): 46. http://dx.doi.org/10.1097/00152192-198801000-00031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 15, no. 2 (March 1988): 94. http://dx.doi.org/10.1097/00152192-198803000-00040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 15, no. 3 (May 1988): 142. http://dx.doi.org/10.1097/00152192-198805000-00036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 15, no. 4 (July 1988): 177. http://dx.doi.org/10.1097/00152192-198807000-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

&NA;, &NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 15, no. 5 (September 1988): 212–13. http://dx.doi.org/10.1097/00152192-198809000-00042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 16, no. 1 (January 1989): 46. http://dx.doi.org/10.1097/00152192-198901000-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 16, no. 4 (July 1989): 183. http://dx.doi.org/10.1097/00152192-198907000-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

&NA;, &NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 16, no. 5 (September 1989): 225–26. http://dx.doi.org/10.1097/00152192-198909000-00031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 16, no. 6 (November 1989): 269. http://dx.doi.org/10.1097/00152192-198911000-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 17, no. 1 (January 1990): 38. http://dx.doi.org/10.1097/00152192-199001000-00032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

&NA;, &NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 17, no. 3 (May 1990): 125. http://dx.doi.org/10.1097/00152192-199005000-00031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 18, no. 4 (July 1991): 143. http://dx.doi.org/10.1097/00152192-199107000-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 18, no. 5 (September 1991): 173. http://dx.doi.org/10.1097/00152192-199109000-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 18, no. 6 (November 1991): 207. http://dx.doi.org/10.1097/00152192-199111000-00023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

&NA;. "Pharmacology." Journal of Wound, Ostomy and Continence Nursing 19, no. 2 (March 1992): 72. http://dx.doi.org/10.1097/00152192-199203000-00025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Perazella, Mark A., and Chirag Parikh. "Pharmacology." American Journal of Kidney Diseases 46, no. 6 (December 2005): 1129–39. http://dx.doi.org/10.1053/j.ajkd.2005.07.051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;, &NA;. "PHARMACOLOGY." Journal of Developmental & Behavioral Pediatrics 11, no. 1 (February 1990): 41–42. http://dx.doi.org/10.1097/00004703-199002000-00020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

&NA;. "PHARMACOLOGY." Inpharma Weekly &NA;, no. 829 (March 1992): 20–21. http://dx.doi.org/10.2165/00128413-199208290-00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Lewis, Keith P., and Glynne D. Stanley. "Pharmacology." International Anesthesiology Clinics 37, no. 4 (1999): 73–86. http://dx.doi.org/10.1097/00004311-199903740-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

LeBel, Alyssa A. "Pharmacology." Journal of Pediatric Gastroenterology and Nutrition 47, no. 5 (November 2008): 703–5. http://dx.doi.org/10.1097/01.mpg.0000338966.70550.d1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

&NA;. "Pharmacology." Survey of Anesthesiology 30, no. 4 (August 1986): 194. http://dx.doi.org/10.1097/00132586-198608000-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Gylys, Karen Hoppens. "Pharmacology." Journal of Cardiovascular Nursing 12, no. 3 (April 1998): 52–56. http://dx.doi.org/10.1097/00005082-199804000-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Jeevendra Martyn, J. A., David J. Greenblatt, and Darrell R. Abernathy. "Pharmacology." Journal of Burn Care & Rehabilitation 8, no. 1 (January 1987): 77. http://dx.doi.org/10.1097/00004630-198701000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Burnham, Nora, and Donna L. Betcher. "Pharmacology." Journal of the Association of Pediatric Oncology Nurses 6, no. 1 (January 1989): 23–25. http://dx.doi.org/10.1177/104345428900600109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Pharmacology' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography